{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:55:07Z","timestamp":1793735707205,"version":"4.6.1"},"reference-count":62,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDR"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Latent Onset Autoimmune Diabetes in Adults (LADA) is an autoimmune disorder\nbetween T1DM and T2DM and is often misdiagnosed as T2DM due to its late-onset. The disease\nis characterized by \u03b2-cell failure and slow progression to insulin dependence. Early diagnosis is\nsignificant in limiting disease progression. C-peptide levels and autoantibodies against \u03b2-cells are\nthe most critical diagnostic biomarkers in LADA. The review aims to provide an overview of the\nbiomarkers used to diagnose LADA, and the following treatment approaches. We have summarized\nLADA's pathophysiology and the autoantibodies involved in the condition, diagnostic approaches,\nand challenges. There are clear shortcomings concerning the feasibility of autoantibody\ntesting. Finally, we have explored the treatment strategies involved in the management of LADA.\nIn conclusion, the usual management includes treatment with metformin and the addition of low\ndoses of insulin. Newer oral hypoglycaemic agents, such as GLP-1RA and DPP-4 inhibitors, have\nbeen brought into use. Since the disease is not entirely understood at the research level and in clinical\npractice, we hope to encourage further research in this field to assess its prevalence. Large randomized\ncontrolled trials are required to compare the efficacy of different available treatment options.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573399818666220324095918","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T04:13:02Z","timestamp":1648181582000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Diagnostic Dilemmas and Current Treatment Approaches in Latent Onset\nAutoimmune Diabetes in Adults: A Concise Review"],"prefix":"10.2174","volume":"19","author":[{"given":"Chitra","family":"Vellapandian","sequence":"first","affiliation":[{"name":"Department of Pharmacology, SRM Institute\nof Science and Technology (SRMIST) (Formerly SRM University), Kattankulathur, Chengalpattu District, Chennai -\n603203, Tamilnadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Chandran","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, SRM Institute of Science and Technology (SRMIST) (Formerly SRM University),\nKattankulathur, Chengalpattu District, Chennai - 603203, Tamilnadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankul","family":"Singh S.","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, SRM Institute\nof Science and Technology (SRMIST) (Formerly SRM University), Kattankulathur, Chengalpattu District, Chennai -\n603203, Tamilnadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.diabres.2016.09.013","volume":"121","author":"Duvnjak L.","year":"2016","unstructured":"Duvnjak L.; Blaslov K.; Vu&#x10D;i\u0107 Lovren&#x10D;i\u0107 M, Kne&#x17E;evi\u0107 \u0106u\u0107a J. Persons with latent autoimmune diabetes in adults express higher dipeptidyl peptidase-4 activity compared to persons with type 2 and type 1 diabetes. Diabetes Res Clin Pract 2016,121,119-126","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"145177","DOI":"10.1016\/j.gene.2020.145177","volume":"767","author":"Chen W.","year":"2021","unstructured":"Chen W.; Chen X.; Zhang M.; Huang Z.; The association of human leukocyte antigen class II (HLA II) haplotypes with the risk of Latent Autoimmune Diabetes of Adults (LADA): Evidence based on available data. Gene 2021,767,145177","journal-title":"Gene"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.maturitas.2020.04.014","volume":"137","author":"Maddaloni E.","year":"2020","unstructured":"Maddaloni E.; Moretti C.; Mignogna C.; Buzzetti R.; Adult-onset autoimmune diabetes in 2020: An update. Maturitas 2020,137,37-44","journal-title":"Maturitas"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.31080\/ASPS.2020.04.0590","volume":"4","author":"Poojith N.","year":"2020","unstructured":"Poojith N.; Kumar Rathinam K.; Sabarathinam S.; Progression of type-2 diabetes mellitus associated with pulmonary tuberculosis sequelae in a 60-year-old hypertensive patient: A multifactorial case report with literature review. Act Scie Pharma 2020,4(10),12-14","journal-title":"Act Scie Pharma"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41574-019-0254-y","volume":"15","author":"Ilonen J.","year":"2019","unstructured":"Ilonen J.; Lempainen J.; Veijola R.; The heterogeneous pathogenesis of type 1 diabetes mellitus. Nat Rev Endocrinol 2019,15(11),635-650","journal-title":"Nat Rev Endocrinol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.pcd.2020.07.008","volume":"15","author":"Moosaie F.","year":"2021","unstructured":"Moosaie F.; Meftah N.; Deravi N.; Prevalence of diabetes-associated autoantibodies among patients presenting with type 2 diabetes and related metabolic differences. Prim Care Diabetes 2021,15(1),169-174","journal-title":"Prim Care Diabetes"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"908","DOI":"10.2337\/dc12-0931","volume":"36","author":"Hawa M.I.","year":"2013","unstructured":"Hawa M.I.; Kolb H.; Schloot N.; Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diabetes Care 2013,36(4),908-913","journal-title":"Diabetes Care"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.2337\/diabetes.53.12.3193","volume":"53","author":"Zinman B.","year":"2004","unstructured":"Zinman B.; Kahn S.E.; Haffner S.M.; O\u2019Neill M.C.; Heise M.A.; Freed M.I.; Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes 2004,53(12),3193-3200","journal-title":"Diabetes"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.tem.2018.07.001","volume":"29","author":"Mishra R.","year":"2018","unstructured":"Mishra R.; Hodge K.M.; Cousminer D.L.; Leslie R.D.; Grant S.F.A.; A global perspective of latent autoimmune diabetes in adults. Trends Endocrinol Metab 2018,29(9),638-650","journal-title":"Trends Endocrinol Metab"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3803\/EnM.2018.33.2.147","volume":"33","author":"Pozzilli P.","year":"2018","unstructured":"Pozzilli P.; Pieralice S.; Latent autoimmune diabetes in adults: Current status and new horizons. Endocrinol Metab (Seoul) 2018,33(2),147-159","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1089\/met.2017.0103","volume":"15","author":"Kumar A.","year":"2017","unstructured":"Kumar A.; de Leiva A.; Latent autoimmune diabetes in adults in North Indian Region: Assessment of &#x3B2;-cell function, metabolic and immunological features. Metab Syndr Relat Disord 2017,15(10),494-499","journal-title":"Metab Syndr Relat Disord"},{"key":"ref=12","first-page":"1395","volume":"12","author":"Sabarathinam S.","year":"2019","unstructured":"Sabarathinam S.; Rajanandh M.G.; Seenivasan P.; Prevalence of metabolic syndrome in diabetic patients attending a diabetic clinic in a tertiary care hospital. Drug Invention Today 2019,12(7),1395-1398","journal-title":"Drug Invention Today"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"580202","DOI":"10.5402\/2012\/580202","volume":"2012","author":"Brahmkshatriya P.P.","year":"2012","unstructured":"Brahmkshatriya P.P.; Mehta A.A.; Saboo B.D.; Goyal R.K.; Characteristics and prevalence of Latent Autoimmune Diabetes in Adults (LADA). ISRN Pharmacol 2012,2012,580202","journal-title":"ISRN Pharmacol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.diabres.2008.01.024","volume":"80","author":"Murao S.","year":"2008","unstructured":"Murao S.; Kondo S.; Ohashi J.; Anti-thyroid peroxidase antibody, IA-2 antibody, and fasting C-peptide levels predict beta cell failure in patients with latent autoimmune diabetes in adults (LADA)--a 5-year follow-up of the Ehime study. Diabetes Res Clin Pract 2008,80(1),114-121","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.diabres.2006.08.013","volume":"76","author":"Yang Z.","year":"2007","unstructured":"Yang Z.; Zhou Z.; Huang G.; The CD4(+) regulatory T-cells is decreased in adults with latent autoimmune diabetes. Diabetes Res Clin Pract 2007,76(1),126-131","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"451","DOI":"10.4093\/dmj.2018.0190","volume":"42","author":"Pieralice S.","year":"2018","unstructured":"Pieralice S.; Pozzilli P.; Latent autoimmune diabetes in adults: A review on clinical implications and management. Diabetes Metab J 2018,42(6),451-464","journal-title":"Diabetes Metab J"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"e3480","DOI":"10.1002\/dmrr.3480","author":"Huang J.","year":"2021","unstructured":"Huang J.; Pearson J.A.; Wong F.S.; Wen L.; Zhou Z.; Innate immunity in latent autoimmune diabetes in adults. Diabetes Metab Res Rev 2021,e3480","journal-title":"Diabetes Metab Res Rev"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/01.mjt.0000178767.67857.63","volume":"12","author":"Yoon J.W.","year":"2005","unstructured":"Yoon J.W.; Jun H.S.; Autoimmune destruction of pancreatic beta cells. Am J Ther 2005,12(6),580-591","journal-title":"Am J Ther"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0065-2776(08)00803-1","volume":"100","author":"Uibo R.","year":"2008","unstructured":"Uibo R.; Lernmark A.; GAD65 autoimmunity-clinical studies. Adv Immunol 2008,100,39-78","journal-title":"Adv Immunol"},{"key":"ref=20","first-page":"297","volume":"28","author":"Falorni A.","year":"2003","unstructured":"Falorni A.; Aspetti immunologici e genetici del diabete autoimmune latente dell\u2019adulto. Minerva Endocrinol 2003,28(4),297-312","journal-title":"Minerva Endocrinol"},{"key":"ref=21","first-page":"81","volume":"1079","author":"Ola T.","year":"2006","unstructured":"Ola T.; David R.; Leslie G.;  Progression of Autoimmune Diabetes 2006,1079(1),81-89","journal-title":"Progression of Autoimmune Diabetes"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.diabres.2006.12.013","volume":"77","author":"Chiu H.K.","year":"2007","unstructured":"Chiu H.K.; Tsai E.C.; Juneja R.; Equivalent insulin resistance in latent autoimmune diabetes in adults (LADA) and type 2 diabetic patients. Diabetes Res Clin Pract 2007,77(2),237-244","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"767","DOI":"10.4103\/ijmr.IJMR_1563_15","volume":"145","author":"Badal D.","year":"2017","unstructured":"","journal-title":"Indian J Med Res"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1210\/clinem\/dgaa549","volume":"105","author":"Hjort R.","year":"2020","unstructured":"Hjort R.; Ahlqvist E.; Andersson T.; Physical activity, genetic susceptibility, and the risk of latent autoimmune diabetes in adults and type 2 diabetes. J Clin Endocrinol Metab 2020,105(11),105","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"178","DOI":"10.2174\/1573399814666180716150253","volume":"15","author":"Carlsson S.","year":"2019","unstructured":"Carlsson S.; Environmental (Lifestyle) risk factors for LADA. Curr Diabetes Rev 2019,15(3),178-187","journal-title":"Curr Diabetes Rev"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"E759","DOI":"10.1152\/ajpendo.2000.278.5.E759","volume":"278","author":"Wahren J.","year":"2000","unstructured":"Wahren J.; Ekberg K.; Johansson J.; Role of C-peptide in human physiology. Am J Physiol Endocrinol Metab 2000,278(5),E759-E768","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=27","author":"Rajkumar V.","year":"2021","unstructured":"Rajkumar V.; Levine S.; Latent Autoimmune Diabetes [Internet]. Ncbi.nlm.nih.gov. [cited 12 October 2021]. Available from: 2021"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/01.mjt.0000102372.28723.2b","volume":"11","author":"Bell D.S.","year":"2004","unstructured":"Bell D.S.; Ovalle F.; The role of C-peptide levels in screening for latent autoimmune diabetes in adults. Am J Ther 2004,11(4),308-311","journal-title":"Am J Ther"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/dme.12700","volume":"32","author":"Laugesen E.","year":"2015","unstructured":"Laugesen E.; &#xD8;stergaard J.A.; Leslie R.D.; Latent autoimmune diabetes of the adult: Current knowledge and uncertainty. Diabet Med 2015,32(7),843-852","journal-title":"Diabet Med"},{"key":"ref=30","first-page":"199","volume":"15","author":"S&#xF8;rgjerd E.","year":"2018","unstructured":"S&#xF8;rgjerd E.; Type 1 diabetes-related autoantibodies in different forms of Diabetes. Curr Diabetes Rev 2018,15(3),199-204","journal-title":"Curr Diabetes Rev"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1007\/s00125-002-0940-4","volume":"45","author":"Mallone R.","year":"2002","unstructured":"Mallone R.; Ortolan E.; Pinach S.; Anti-CD38 autoantibodies: characterisation in new-onset type I diabetes and Latent Autoimmune Diabetes of the Adult (LADA) and comparison with other islet autoantibodies. Diabetologia 2002,45(12),1667-1677","journal-title":"Diabetologia"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00592-010-0250-0","volume":"48","author":"Jin P.","year":"2011","unstructured":"Jin P.; Huang G.; Lin J.; Luo S.; Zhou Z.; Epitope analysis of GAD65 autoantibodies in adult-onset type 1 diabetes and latent autoimmune diabetes in adults with thyroid autoimmunity. Acta Diabetol 2011,48(2),149-155","journal-title":"Acta Diabetol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1196\/annals.1337.019","volume":"1037","author":"Li X.","year":"2004","unstructured":"Li X.; Zhou Z.G.; Huang G.; Optimal cutoff point of glutamate decarboxylase antibody titers in differentiating two subtypes of adult-onset latent autoimmune diabetes. Ann N Y Acad Sci 2004,1037,122-126","journal-title":"Ann N Y Acad Sci"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1464-5491.2008.02497.x","volume":"25","author":"Desai M.","year":"2008","unstructured":"Desai M.; Clark A.; Autoimmune diabetes in adults: Lessons from the UKPDS. Diabet Med 2008,25(Suppl. 2),30-34","journal-title":"Diabet Med"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.2337\/diab.44.11.1290","volume":"44","author":"Myers M.A.","year":"1995","unstructured":"Myers M.A.; Rabin D.U.; Rowley M.J.; Pancreatic islet cell cytoplasmic antibody in diabetes is represented by antibodies to islet cell antigen 512 and glutamic acid decarboxylase. Diabetes 1995,44(11),1290-1295","journal-title":"Diabetes"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3389\/fendo.2018.00260","volume":"9","author":"Li R.","year":"2018","unstructured":"Li R.; Huang J.; Yu Y.; Yang Y.; islet autoantibody patterns in patients with type 2 diabetes aged 60 and higher: A cross-sectional study in a Chinese Hospital. Front Endocrinol (Lausanne) 2018,9,260","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.2337\/diabetes.52.5.1137","volume":"52","author":"Hanifi-Moghaddam P.","year":"2003","unstructured":"Hanifi-Moghaddam P.; Schloot N.C.; Kappler S.; Seissler J.; Kolb H.; An association of autoantibody status and serum cytokine levels in type 1 diabetes. Diabetes 2003,52(5),1137-1142","journal-title":"Diabetes"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.2337\/diabetes.54.suppl_2.S52","volume":"54","author":"Pihoker C.","year":"2005","unstructured":"Pihoker C.; Gilliam L.K.; Hampe C.S.; Lernmark A.; Autoantibodies in diabetes. Diabetes 2005,54(Suppl. 2),S52-S61","journal-title":"Diabetes"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.4049\/jimmunol.161.5.2648","volume":"161","author":"Bonifacio E.","year":"1998","unstructured":"Bonifacio E.; Lampasona V.; Bingley P.J.; IA-2 (islet cell antigen 512) is the primary target of humoral autoimmunity against type 1 diabetes-associated tyrosine phosphatase autoantigens. J Immunol 1998,161(5),2648-2654","journal-title":"J Immunol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00125-005-1691-9","volume":"48","author":"Bottazzo G.F.","year":"2005","unstructured":"Bottazzo G.F.; Bosi E.; Cull C.A.; IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). Diabetologia 2005,48(4),703-708","journal-title":"Diabetologia"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/dmrr.998","volume":"25","author":"Siljander H.","year":"2009","unstructured":"Siljander H.; H&#xE4;rk&#xF6;nen T.; Hermann R.; Role of insulin autoantibody affinity as a predictive marker for type 1 diabetes in young children with HLA-conferred disease susceptibility. Diabetes Metab Res Rev 2009,25(7),615-622","journal-title":"Diabetes Metab Res Rev"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.beem.2004.11.010","volume":"19","author":"Falorni A.","year":"2005","unstructured":"Falorni A.; Brozzetti A.; Diabetes-related antibodies in adult diabetic patients. Best Pract Res Clin Endocrinol Metab 2005,19(1),119-133","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.tem.2014.03.008","volume":"25","author":"Davidson H.W.","year":"2014","unstructured":"Davidson H.W.; Wenzlau J.M.; O\u2019Brien R.M.; Zinc transporter 8 (ZnT8) and &#x3B2; cell function. Trends Endocrinol Metab 2014,25(8),415-424","journal-title":"Trends Endocrinol Metab"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2337\/dc08-2305","volume":"33","author":"Lampasona V.","year":"2010","unstructured":"Lampasona V.; Petrone A.; Tiberti C.; Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes: Non Insulin Requiring Autoimmune Diabetes (NIRAD) 4. Diabetes Care 2010,33(1),104-108","journal-title":"Diabetes Care"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.clinbiochem.2016.06.008","volume":"50","author":"Hussein H.","year":"2017","unstructured":"Hussein H.; Ibrahim F.; Sobngwi E.; Gautier J.F.; Boudou P.; Zinc transporter 8 autoantibodies assessment in daily practice. Clin Biochem 2017,50(1-2),94-96","journal-title":"Clin Biochem"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1046\/j.1365-2265.2000.00983.x","volume":"52","author":"Gambelunghe G.","year":"2000","unstructured":"Gambelunghe G.; Forini F.; Laureti S.; Increased risk for endocrine autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibodies. Clin Endocrinol (Oxf) 2000,52(5),565-573","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1007\/s00125-002-0886-6","volume":"45","author":"Antonelli A.","year":"2002","unstructured":"Antonelli A.; Tuomi T.; Nannipieri M.; Autoimmunity to CD38 and GAD in Type I and Type II diabetes: CD38 and HLA genotypes and clinical phenotypes. Diabetologia 2002,45(9),1298-1306","journal-title":"Diabetologia"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1007\/s00125-011-2088-6","volume":"54","author":"Pham M.N.","year":"2011","unstructured":"Pham M.N.; Hawa M.I.; Pfleger C.; Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: Action LADA 4. Diabetologia 2011,54(7),1630-1638","journal-title":"Diabetologia"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.2337\/dc16-0293","volume":"39","author":"Schloot N.C.","year":"2016","unstructured":"Schloot N.C.; Pham M.N.; Hawa M.I.; Inverse relationship between organ-specific autoantibodies and systemic immune mediators in type 1 diabetes and type 2 diabetes: Action LADA 11. Diabetes Care 2016,39(11),1932-1939","journal-title":"Diabetes Care"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.cyto.2012.01.002","volume":"58","author":"Strom A.","year":"2012","unstructured":"Strom A.; Menart B.; Simon M.C.; Cellular interferon-&#x3B3; and interleukin-13 immune reactivity in type 1, type 2 and latent autoimmune diabetes: Action LADA 6. Cytokine 2012,58(2),148-151","journal-title":"Cytokine"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2337\/ds15-0047","volume":"29","author":"O\u2019Neal K.S.","year":"2016","unstructured":"O\u2019Neal K.S.; Johnson J.L.; Panak R.L.; Recognizing and appropriately treating latent autoimmune diabetes in adults. Diabetes Spectr 2016,29(4),249-252","journal-title":"Diabetes Spectr"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"e1270","DOI":"10.1097\/MJT.0000000000000349","volume":"23","author":"Chatzianagnostou K.","year":"2016","unstructured":"Chatzianagnostou K.; Iervasi G.; Vassalle C.; Challenges of LADA diagnosis and treatment: Lessons from 2 case reports. Am J Ther 2016,23(5),e1270-e1274","journal-title":"Am J Ther"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrendo.2017.99","volume":"13","author":"Buzzetti R.","year":"2017","unstructured":"Buzzetti R.; Zampetti S.; Maddaloni E.; Adult-onset autoimmune diabetes: Current knowledge and implications for management. Nat Rev Endocrinol 2017,13(11),674-686","journal-title":"Nat Rev Endocrinol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/5584_2020_533","volume":"1307","author":"Hern&#xE1;ndez M.","year":"2021","unstructured":"Hern&#xE1;ndez M.; Mauricio D.; Latent autoimmune diabetes in adults: a review of clinically relevant issues. Adv Exp Med Biol 2021,1307,29-41","journal-title":"Adv Exp Med Biol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.2337\/dbi20-0017","volume":"69","author":"Buzzetti R.","year":"2020","unstructured":"Buzzetti R.; Tuomi T.; Mauricio D.; Management of latent autoimmune diabetes in adults: A consensus statement from an international expert panel. Diabetes 2020,69(10),2037-2047","journal-title":"Diabetes"},{"key":"ref=56","author":"Rajkumar V","year":"2021","unstructured":"Rajkumar V; Levine SN; Stat Pearls [Internet].  Latent Autoimmune Diabetes Jul 18 [cited 2021 Dec 24]; Available from: 2021","journal-title":"Latent Autoimmune Diabetes"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1210\/clinem\/dgaa710","volume":"106","author":"Broome D.T.","year":"2021","unstructured":"Broome D.T.; Pantalone K.M.; Kashyap S.R.; Philipson L.H.; Approach to the Patient with MODY-Monogenic Diabetes. J Clin Endocrinol Metab 2021,106(1),237-250","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"637945","DOI":"10.3389\/fgene.2021.637945","volume":"12","author":"Fedotkina O.","year":"2021","unstructured":"Fedotkina O.; Sulaieva O.; Ozgumus T.; Novel reclassification of adult diabetes is useful to distinguish stages of &#x3B2;-cell function linked to the risk of vascular complications: The DOLCE Study from Northern Ukraine. Front Genet 2021,12,637945","journal-title":"Front Genet"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.2337\/dc20-2834","volume":"44","author":"Jones A.G.","year":"2021","unstructured":"Jones A.G.; McDonald T.J.; Shields B.M.; Hagopian W.; Hattersley A.T.; Latent Autoimmune Diabetes of Adults (LADA) is likely to represent a mixed population of autoimmune (type 1) and nonautoimmune (type 2) diabetes. Diabetes Care [Internet]2021,44(6),1243-1251","journal-title":"Diabetes Care"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s00125-012-2759-y","volume":"56","author":"Andersen C.D.","year":"2013","unstructured":"Andersen C.D.; Bennet L.; Nystr&#xF6;m L.; Worse glycaemic control in LADA patients than in those with type 2 diabetes, despite a longer time on insulin therapy. Diabetologia 2013,56(2),252-258","journal-title":"Diabetologia"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1530\/EJE-10-0901","volume":"164","author":"Thunander M","year":"2011","unstructured":"Thunander M; Thorgeirsson H; T&#xF6;rn C; Petersson C; Landin-Olsson M.; &#x3B2;-cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: A 3-year follow-up. Eur J Endocrinol 2011,164(2),239-245","journal-title":"Eur J Endocrinol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"S246","DOI":"10.2337\/dc09-S317","volume":"32","author":"Cernea S","year":"2009","unstructured":"Cernea S; Buzzetti R; Pozzilli P.; &#x3B2;-cell protection and therapy for latent autoimmune diabetes in adults. Diabetes Care 2009,32(Suppl. 2),S246-S252","journal-title":"Diabetes Care"}],"container-title":["Current Diabetes Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573399818666220324095918","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/202561\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573399818666220324095918","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T12:43:17Z","timestamp":1679316197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/202561\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573399818666220324095918","relation":{},"ISSN":["1573-3998"],"issn-type":[{"value":"1573-3998","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-10-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e240322202561"}}